Volume 27, Issue 2, June 2016
Sign in to download the Issue in PDF format.
1726281772
Mediterr J Rheumatol 2016;27(2):34-5
Article Links
How to reduce costs of biological treatments in patients with Rheumatoid Arthritis: The Dutch experience
Keywords: Rheumatoid Arthritis, DMARDs, csDMARDs, bDMARDs, biosimilars, tapering, biological treatment, remission
References
- Kievit W, Fransen J, Adang E M, et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 2011;50:196-203.
- Goekoop-Ruiterman Y P M, De Vries-Bouwstra J K, Allaart C F, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
- Landewé R B M, Boers M, Verhoeven A C, et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
- Bakker M F, Jacobs J W G, Welsing P M J, et al. Clinical and epidemiological research: Concise report: Early clinical response to treatment predicts 5-year outcome in RA patients: follow-up results from the CAMERA study. Ann Rheum Dis 2011;70:1099-103.
- Vermeer M, Kuper H H, Hoekstra M, et al. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum 2011;63(10):2865-72.
- de Jong P H, Hazes J M, Han H K, et al. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 2014;73:1331-9.
- Ten Wolde S, Breedveld F C, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-52.
- Moghadam M G, Vonkeman H E, ten Klooster P M, et al. Stopping Tumor Necrosis Factor-inhibitors in Patients with Established Rheumatoid Arthritis in Remission or Stable Low Disease Activity: A Pragmatic Randomized Multicenter Open-Label Controlled Trial. Arthritis Rheum 2016;68(8):1810-7.
- van Herwaarden N, van der Maas A, Minten M J M, et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial BMJ 2015;350:h1389.